Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY4152199 |
| Synonyms | |
| Therapy Description |
LY4152199 is a human bispecific antibody that targets TNFRSF13C (BAFF-R) on B-cells and CD3 on T-cells, which may lead to T-cell-mediated cytotoxicity towards TNFRSF13C (BAFF-R)-expressing tumor cells (Blood 144 (Suppl 1):2785). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY4152199 | LY 4152199 | CD3 Antibody 119 | LY4152199 is a human bispecific antibody that targets TNFRSF13C (BAFF-R) on B-cells and CD3 on T-cells, which may lead to T-cell-mediated cytotoxicity towards TNFRSF13C (BAFF-R)-expressing tumor cells (Blood 144 (Suppl 1):2785). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07101328 | Phase I | LY4152199 | A Study of LY4152199 in Participants With Previously Treated B-cell Cancers and Leukemia (BAF-FRontier-1) | Not yet recruiting | USA | POL | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 2 |